50 results about "Tetanus" patented technology

1. Name of this design product: Skin Test Judgment Ruler. 2. Application of this design: This design is used for skin tests of penicillin, cephalosporins, tetanus and tuberculin. 3. The key design feature of this product is its pattern. 4. The image or photograph that best illustrates the design's key features: the front view. 5. This design is a thin product, so the left view is omitted; this design is a thin product, so the right view is omitted; this design is a thin product, so the top view is omitted; this design is a thin product, so the bottom view is omitted.

The utility model discloses a tetanus fermentation tank tail gas treatment device which comprises a fermentation tank, a tail gas discharge pipeline of the fermentation tank is provided with a one-way valve, and the fermentation tank is connected with a waste gas absorption alkali barrel through the tail gas discharge pipeline; the tail end of the tail gas discharge pipeline is connected with a gas inlet pipeline; and the gas inlet pipeline is positioned in the waste gas absorption alkali barrel. According to the mode, the harm caused by hydrogen sulfide in tail gas emission of a broken fermentation tank can be solved, the hydrogen sulfide in the tail gas is fully absorbed by a large amount of alkali liquor, the situation that odor and toxic gas appear in an indoor working place and harm health of people is avoided, and meanwhile high energy cost and safety risks are avoided.

The plasma mixing device for tetanus human immune globulin comprises a bottom plate, a sliding table is slidably connected to the top of the bottom plate, a driving assembly is arranged in the sliding table, a supporting rod is arranged at the top of the driving assembly and rotatably connected with the sliding table, a guiding assembly is arranged at the top of the supporting rod, and the guiding assembly is rotatably connected with the sliding table. A transmission rod is arranged at the top of the guide assembly, a supporting table is rotationally connected to the outer side of the transmission rod, the bottom of the supporting table is fixedly connected with the top of the sliding table, a cylinder is fixedly connected to the top of the transmission rod, a screw cap is in threaded connection with the top of the cylinder, and a disc is arranged on the rear side of the driving assembly. A cylindrical rod is arranged on the rear side of the disc, a limiting frame is connected to the rear side of the cylindrical rod in a sliding mode, and the problems that a simple stirring or shaking mode is mostly adopted in an existing uniform mixing device and method, the efficiency of the mode is low, uneven distribution of components in plasma is easily caused, and the quality and the effect of a final product are affected are effectively solved.

The invention discloses a recombinant tetanus toxin protein rTT as well as a preparation method and application thereof, the recombinant protein sequentially contains a His tag, a modified exogenous polypeptide and two tetanus toxin fragments connected in series through flexible polypeptides from the N end to the C end, the two tetanus toxin fragments connected in series form two intramolecular disulfide bonds in a molecule through double mutation, and the tetanus toxin fragments are connected in series through flexible polypeptides. Coding nucleotide of the recombinant protein is expressed by escherichia coli BL21 (DE3), induced at low temperature and purified, and target protein with the purity larger than or equal to 95% can be obtained. A subunit vaccine prepared from the protein and a two-way oil adjuvant ISA201 enables mice to achieve 100% protection under 100 LD50 challenge dose, the protection effect is better than that of truncated tetanus toxin heavy chain fragment TTc protein, and the recombinant protein can be used for tetanus prevention vaccines and serological diagnostic reagents.

Disclosed in the present invention is a pharmaceutical combination comprising an adsorbed tetanus vaccine and an antibody or an antigen-binding fragment thereof against tetanus toxin. The pharmaceutical combination is used for preventing and / or treating tetanus.

The present invention relates to a nucleic acid molecule for modulating neuromuscular transmission, said nucleic acid molecule comprising a sequence encoding one or more motor endplate receptors or fragments thereof. The present invention further relates to a fusion protein, preferably comprising one or more features of one or more of the foregoing Claims, said fusion protein comprising a motor endplate receptor and / or fragments thereof, wherein said motor endplate receptor is an acetylcholine receptor (AChR), a muscle-specific tyrosine kinase (MuSK) receptor, and / or a glutamate receptor, and / or fragments thereof, and / or a neurotoxin, wherein said neurotoxin is botulinum toxin (BoNT) and / or tetanus toxin.

The invention discloses a preparation method of a proteoglycan protein conjugate carrying a specified connection site. The method comprises the following steps: carrying out recombinant expression on a recombinant tetanus toxin heavy chain C fragment rTTHc containing a Sortase A 7M ligase recognition sequence, introducing O, O '-(ethane-1, 2-diyl) bis (hydroxylamine) as a nucleophilic reagent into the C tail end of the rTTHc under the action of ligase Sortase A 7M, and carrying out specific condensation reaction on the C tail end of the rTTHc as a unique chemical reaction site and polysaccharide carrying an aldehyde group functional group to obtain the tetanus toxin heavy chain C fragment rTTHc. Therefore, polysaccharide protein conjugates with definite polysaccharide and protein connection sites are produced. According to the invention, the problem that the key antigen epitope of the carrier protein and the heterogeneity of the product are possibly damaged by the traditional random modification strategy is solved, the antigen epitope of the carrier protein is prevented from being damaged to a great extent, and a reliable technical scheme is provided for preparing the polysaccharide conjugate vaccine with high quality and high immunogenicity.

The invention relates to the technical field of biological pharmacy, and discloses a tetanus human immune globulin preparation method, which comprises: S1, plasma pretreatment: taking anticoagulant plasma with a tetanus antibody titer of more than or equal to 10 IU / mL, and carrying out filtration treatment on the anticoagulant plasma; an improved self-adaptive algorithm is adopted to determine various parameters in the extraction process, S3, composite chromatographic purification, S4, collaborative virus inactivation, and S5, preparation preparation. According to the method, through linkage of an improved adaptive particle swarm-response surface coupling algorithm, first, 40 groups of initial sample sets are constructed by Latin hypercube sampling, a double-response surface model (R2gt; 0.95) is fitted by using a quadratic polynomial, and then a particle swarm depends on the model to predict fitness and dynamically adjust inertia weight balance optimization. By means of the linkage, the TT-IgG extraction rate is increased by 13-15%, the impurity protein removal rate is increased by 14-16%, RSD of three parallel experiments is smaller than or equal to 3%, and it is guaranteed that parameters are accurate and repeated.

The invention provides an anti-tetanus antibody as well as preparation and application thereof, and relates to the field of antibodies. The amino acid sequence of the tetanus-resistant antibody heavy chain CDR is as shown in SEQ ID NO: 1-3; the amino acid sequence of the light chain CDR of the antibody is as shown in SEQ ID NO: 4-6. The antibody disclosed by the invention is high in activity and affinity, and has the application prospect of preparing a medicine for preventing and / or treating tetanus or a product for detecting the tetanus toxin level with a non-diagnostic purpose and the like.

Provided herein are antigenic peptides comprising the SARS-COV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, non-toxic tetanus toxin variant (i.e., a modified tetanus toxin or “MTT”) and vaccine compositions comprising the same. In addition, provided herein are methods for making and using CRBD-MTT fusion proteins as immunogenic agents.

The present disclosure provides an anti-tetanus toxin neutralizing antibody as a new generation of tetanus passive immunization preparation. The antibody can be fully human, which can specifically bind to full-length tetanus toxin and its AB fragment, has high affinity, high specificity, small toxic side effects, avoids the problems of large adverse reactions and short half-life of animal-derived monoclonal antibodies, and is prepared in large quantities by mammalian cells, and has clear and stable components.

The invention discloses a technology for removing viruses from tetanus human immune globulin through a nano film. The process comprises the following steps: pretreating a feed liquid, so that the protein concentration of the feed liquid is 50-60g / L, the pH is 3.8-4.4, and the feed liquid contains 90-110g / L maltose and 50-150mmol / L sodium chloride; then, the feed liquid is subjected to two-stage filtration through a 0.1-micron nylon pre-filtration membrane bag with negative charges and a 20-nm regenerated cellulose (RC) virus removal membrane bag in sequence. According to the process, through optimizing the physical and chemical state of the feed liquid and the synergistic effect of the feed liquid and the functionalized filter membrane, the protein aggregation is effectively inhibited, the membrane pollution is reduced, the virus removal effect is ensured not to be lower than 4log10, the protein load of the RC membrane is remarkably improved to be more than 200L / m, and the product purity is more than or equal to 98%. The invention solves the technical problems of low flux and easy blockage of high-concentration immune globulin in small-aperture virus removal filtration, and is suitable for efficient, safe and large-scale production of blood products.

Disclosed in the present invention is a formulation containing an anti-tetanus toxin antibody, wherein the formulation comprises the anti-tetanus toxin antibody at a concentration of 1-100 mg / mL, and has a pH of 5.0-7.0; and optionally, the formulation further comprises one or more of a surfactant, a pH regulator, a protein protective agent, and an osmotic pressure regulator. The formulation provided by the present invention can effectively maintain the stability of the antibody, so that the antibody is not liable to aggregate, thereby preventing oxidation, denaturation and degradation. In addition, the formulation also maintains the high titer of the antibody against tetanus toxin, and thus has the high biological activity required for preventing or treating tetanus.

Provided are a bispecific antibody and a monoclonal antibody for a tetanus toxin, and uses of the antibodies. The bispecific antibody contains a first antigen-binding fragment and a second antigen-binding fragment which bind to different epitopes of the tetanus toxin, and has activity of neutralizing the tetanus toxin. The monoclonal antibody binds to the tetanus toxin, and has activity of neutralizing the tetanus toxin.

The utility model belongs to the technical field of separation and extraction equipment, and particularly relates to tetanus human immune globulin separation and extraction equipment which comprises a protective shell, a rotating disc is rotatably mounted in the protective shell, a plurality of placement cavities and a first power cavity are formed in the rotating disc, and clamping rods are slidably mounted in the first power cavity and located on the two sides of the placement cavities; one end of the clamping rod penetrates through the power cavity I and extends into the corresponding placing cavity; the driving assembly is located in the protective shell and used for driving the rotating disc to rotate and driving the multiple clamping rods to slide; the fixed block is fixedly mounted on one side of the protective shell, a sliding groove is formed in the fixed block, and a storage tank is slidably mounted in the sliding groove, so that the positions of the plurality of test tubes can be clamped and fixed, the stability of the test tubes during rotation is ensured, and meanwhile, to-be-extracted products in the plurality of test tubes are ensured to be the same; the same time and rotating speed required by separation and extraction of a plurality of test tubes are ensured, and the same quality of separated and extracted products is ensured.

This utility model relates to the technical field of human immunoglobulin preparation devices, and discloses a sampling device for preparing tetanus human immunoglobulin. It includes a sampling cylinder with a low-temperature storage mechanism on its outer wall and an automatic sampling mechanism. The low-temperature storage mechanism includes a first support ring, a supporting outer cylinder fixedly mounted at the bottom of the first support ring, and a second support ring fixedly mounted at the bottom of the supporting outer cylinder. Through the design of the low-temperature storage mechanism, this utility model can store a low-temperature medium in the cavity formed by the first support ring, the supporting outer cylinder, the second support ring, and the copper inner cylinder. The low-temperature medium can pass through the copper inner cylinder to cool the inner cavity of the sampling cylinder, thus achieving the function of low-temperature storage of the sample inside the sampling cylinder. This avoids the problem of sample deterioration during storage due to high ambient temperatures, ensuring the accuracy of biochemical analysis.

Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.

The application discloses a preparation containing an anti-tetanus toxin antibody, the preparation containing the anti-tetanus toxin antibody at a concentration of 1-100 mg / mL and having a pH of 5.0-7.0; and optionally, the preparation further contains one or more of a surfactant, a pH regulator, a protein protective agent and an osmotic pressure regulator. The preparation provided by the application can effectively maintain the stability of the antibody, so that the antibody is not prone to aggregation, oxidation, denaturation and degradation; in addition, the antibody has a high titer of anti-tetanus toxin and high bioactivity required for preventing or treating tetanus.

This invention belongs to the field of veterinary biological products technology, specifically relating to a traditional Chinese medicine composition for improving plasma titer and protecting the liver in tetanus-immunized horses, and its application. The composition consists of the following herbs in parts by weight: Angelica sinensis 20-30 parts, Paeonia lactiflora 20-30 parts, Bupleurum chinense 15-20 parts, Atractylodes macrocephala 25-35 parts, Poria cocos 20-30 parts, and Artemisia capillaris 30-40 parts. Experiments show that the composition of this invention can increase the average IgG titer of culled horses with low titers (initial IgG titer 800-1200 IU / mL) by more than 250 IU / mL after an 18-week immunization cycle, far exceeding the predetermined target of 200 IU / mL. Simultaneously, it significantly increases the immunization pass rate (≥1300 IU / mL) of newly immunized horses from 73.3% in the control group to 93.3%, an absolute increase of 20 percentage points. Furthermore, the area under the IgG titer-time curve (AUC) is 1.3 times higher than that of the control group, indicating a significant increase in the cumulative antibody production throughout the immunization cycle. This invention improves the plasma titer of horses while also protecting the liver, and has good application prospects.

The invention discloses a nano antibody T92-6 of an anti-tetanus toxin Hc structural domain and application of the nano antibody T92-6, and belongs to the field of immunotherapy biotechnology pharmacy. The nano antibody or the antigen binding fragment thereof comprises three complementarity determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the CDR1 is SEQ ID NO: 6, the amino acid sequence of the CDR2 is SEQ ID NO: 7, the amino acid sequence of the CDR3 is SEQ ID NO: 8, and the sequences of the complementarity determining regions are defined according to an IMGT numbering system. The antibody is only combined with THc protein, and poisoning caused by a lethal dose of tetanus toxin (10 * LD50) can be effectively blocked by 5 micrograms of the antibody; after being humanized, the antibody still has better affinity and neutralizing activity, and the antibody with the same dose can still effectively block poisoning caused by tetanus toxin (10 * LD50) with a lethal dose.

The invention provides a nanoparticle protein rePO-TTFC (at) LS as well as a preparation method and application thereof. The protein is composed of rePO (at) LS and a tetanus toxin C fragment TTFC. The recombinant protein SpyCatcher-rePO at LS disclosed by the invention is subjected to induced expression in escherichia coli in a soluble form. According to the present invention, the recombinant protein SpyCatcher-rePO (at) LS can be subjected to covalent binding with the recombinant protein reTTFC-SpyTag through the isopeptide bond so as to form the rePO-TTFC (at) LS duplex nanoparticle vaccine molecule, and the binding condition is simple; the nanoparticle protein can induce an animal body to generate high-level immune response and play an immune protection role, the response speed and protection efficiency of an antibody induced by the nanoparticle protein are obviously superior to those of a monomer rePO and a monomer reTTFC fusion protein, and the nanoparticle protein can be used for preventing and treating pseudomonas aeruginosa and tetanus at the same time.

The present invention relates to the field of biomedical technologies, and more specifically to a modified mRNA vaccine against tetanus and its preparation method. A modified mRNA vaccine against tetanus, characterized in that: the vaccine comprises: (1) mRNA for expressing a tetanus toxin immunogen, the immunogen being one of an Hc protein, an Hc-TRX protein, and an Hn+Hc protein; (2) a vaccine carrier, the vaccine carrier being a liposome nanoparticle that can be utilized by the mRNA. The main advantages of the present invention are: (1) for the first time, the C-terminal domain of the heavy chain of tetanus toxin (Hc), the fusion protein of the C-terminal domain of the heavy chain and thioredoxin (TRX-Hc), and the complete heavy chain of tetanus toxin (Hn+Hc) are selected as antigens to develop a modified mRNA vaccine; (2) the three developed tetanus toxin mRNA vaccines can all effectively induce specific antibody responses.

The invention discloses a nano antibody TL-25 of an anti-tetanus toxin L-HN fragment and application of the nano antibody TL-25, and belongs to the field of immunotherapy biotechnology pharmacy. The nano antibody or the antigen binding fragment thereof comprises three complementarity determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the CDR1 is SEQ ID NO: 6, the amino acid sequence of the CDR2 is SEQ ID NO: 7, the amino acid sequence of the CDR3 is SEQ ID NO: 8, and the sequences of the complementarity determining regions are defined according to an IMGT numbering system. The antibody is only combined with TL-HN protein, and 0.3125 [mu] g of the antibody can effectively block poisoning caused by tetanus toxin (10 * LD50) in a lethal dose; after being humanized, the antibody still has better affinity and neutralizing activity, and the antibody with the same dose can still effectively block poisoning caused by tetanus toxin (10 * LD50) with a lethal dose.

Provided are an anti-tetanus toxin neutralizing antibody and the use thereof as a new-generation tetanus passive immunological preparation. The antibody can be a fully human antibody, has the characteristics of a high affinity, a high specificity, and few toxic side effects, and avoids the problems of strong adverse reactions and a short half-life of animal-derived monoclonal antibodies. Moreover, the antibody can be prepared on a large scale using mammalian cells, and has a clear and stable composition. On the basis of clinical requirements, the exploration and development of an anti-tetanus toxin neutralizing fully-human antibody as a new-generation tetanus passive immunological preparation has great medical value.

The utility model provides a tetanus skin test result interpretation ruler which comprises an interpretation ruler body, a rectangular through groove is formed in the interpretation ruler body along the ruler body, and a convex lens capable of sliding in the through groove in the length direction of the ruler body is clamped in the rectangular through groove; and the auxiliary rulers are arranged below the interpretation ruler main body at intervals, so that the focus points of the convex lenses are positioned on the auxiliary rulers. A medical worker holds the interpretation ruler body by hand, attaches the auxiliary ruler to the skin of a patient, firstly slides the convex lens in the rectangular through groove, meanwhile observes the scale number of the side of the reddish dizziness on the auxiliary ruler, then slides the convex lens to the other side of the reddish dizziness, and observes the scale number of the other side of the reddish dizziness and the scale number of the auxiliary ruler. Therefore, whether allergy occurs or not is judged. The tetanus injection device is easy to use, simple in structure and low in manufacturing cost, allergy and unnecessary medical accidents caused by tetanus injection of a patient are avoided, efficiency is improved, and meanwhile the misjudgment rate is reduced.

The invention discloses a preparation and test method of an immunosensor for tetanus toxin detection. The method comprises the following steps: respectively preparing a tetrachloroauric acid solution and a hexachloroplatinic acid solution, dropwise adding the tetrachloroauric acid solution and the hexachloroplatinic acid solution to the red copper sheet, and drying under an ultraviolet lamp to form a gold-platinum nanoparticle catalyst layer; placing the red copper sheet in a chamber of electron-assisted hot filament chemical vapor deposition system equipment for growing a gold platinum-vertical graphene electrode; dropwise adding a tetanus antibody solution and a bovine serum albumin solution into the gold platinum-vertical graphene electrode to obtain a gold platinum-vertical graphene electrode incubated with bovine serum albumin and a tetanus antibody; a tetanus toxin solution is taken and dropwise added to the gold platinum-vertical graphene electrode incubated with bovine serum albumin and tetanus antibodies, and the immunosensor for tetanus toxin detection is obtained. The method inhibits non-specific adsorption, stabilizes a base line, and supports tetanus toxin low-concentration quantification and subsequent application linkage.

The invention discloses a method and a product for detecting the binding capacity of clostridium neurotoxin and a receptor. The research discovers that the synaptic binding protein Syt1, a Syt1 mutant or Syt2 can be used for promoting glycosylation modification and membrane localization of the synaptic vesicle protein SV2, so that the binding capacity of the synaptic vesicle protein SV2 and botulinum neurotoxin or tetanus toxin is remarkably enhanced. The synaptic binding protein Syt1, Syt1 mutant or Syt2 is prepared into a product for detecting the clostridium neurotoxin, so that the synaptic vesicle protein SV2 can retain natural conformation and post-translational modification sites, and the physiological expression state is effectively simulated, thereby realizing accurate analysis of the binding capacity of the clostridium neurotoxin and the synaptic vesicle protein SV2.

The invention provides a pharmaceutical composition for preventing and / or treating tetanus as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises a recombinant tetanus toxin C fragment as a unique antigen component, an adjuvant and a solvent, wherein the adjuvant is selected from one or more of an aluminum adjuvant, a Toll-like receptor stimulant and saponin, preferably the aluminum adjuvant, and / or the solvent is selected from one or more of a phosphate buffer solution, a citrate buffer solution, a histidine salt buffer solution and a sodium chloride solution, preferably the phosphate buffer solution and / or the sodium chloride solution. The adopted recombinant tetanus natural C fragment (Hc) is non-toxic, formaldehyde inactivation is not needed, meanwhile, the possibility of toxicity reversion is avoided, and the pharmaceutical composition can induce mammals to generate high immune response against tetanus and has good immune persistence.